Microbial species in the mouth could be playing a role in colorectal cancer development, according to new research from epidemiologists at VUMC.
News: Colorectal Cancer
The American Cancer Society now recommends people at average risk be screened for colorectal cancer via colonoscopy, or another method, starting at age 45, rather than at age 50.
Wellington Pham, PhD, and colleagues in Japan, have developed a nanobeacon imaging agent to aid the early detection of colorectal cancer during colonoscopy.
Cancer Research UK has awarded a 20-million-pound grant (about $26 million U.S.) to a team of international investigators, including Vanderbilt’s James Goldenring, MD, PhD, to study inflammation-related cancers.
A large-scale study conducted among East Asians and led by Vanderbilt researchers has identified multiple, previously unknown genetic risk factors for colorectal cancer.
In an article recently published in Cell Reports, James G. Patton, PhD, and colleagues studied how colon cancer cells can secrete long RNAs in carefully regulated ways.
A trans-institutional team of researchers at Vanderbilt University Medical Center and Vanderbilt University has received an $11 million Cancer Moonshot grant to build a single-cell resolution atlas to map out the routes that benign colonic polyps take to progress to colorectal cancer.
A recent study has linked inflammation-driven carcinogenesis in the colon to loss of an important signaling protein called SMAD4.
Calcium plays key roles in cellular signaling, proliferation and death. Previous studies exploring the relationship between dietary calcium intake and colorectal cancer have had contradictory results, perhaps due to no consideration of variation in calcium reabsorption by the kidney.
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.